AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Akebia Therapeutics Inc. (AKBA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.90

-0.08 (-4.04%)

At close: Feb 20, 2025, 3:59 PM

1.90

0.03%

After-hours: Feb 20, 2025, 05:37 PM EST

undefined% (undefined)

Bid	1.9
Market Cap	414.54M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.22
PE Ratio (ttm)	-8.64
Forward PE	n/a
Analyst	Buy

Ask	1.94
Volume	2,406,923
Avg. Volume (20D)	2,152,374
Open	1.98
Previous Close	1.98
Day's Range	1.88 - 1.98
52-Week Range	0.80 - 2.48
Beta	undefined

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 20, 2014

Employees 167

Stock Exchange NASDAQ

Ticker Symbol AKBA

Website https://www.akebia.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for AKBA stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 294.74% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Akebia Therapeutics Inc. is scheduled to release its earnings on Mar 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+6.86%

Akebia Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

3 months ago

-6.5%

Akebia Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

News

1 week ago · seekingalpha.com

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia's declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA's sig...

1 month ago · zacks.com

New Strong Sell Stocks for January 3rd

AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024.

2 months ago · zacks.com

New Strong Sell Stocks for December 5th

AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024.

2 months ago · zacks.com

New Strong Sell Stocks for November 27th

AKBA, ABG and CLH have been added to the Zacks Rank #5 (Strong Sell) List on November 27, 2024.

3 months ago · zacks.com

New Strong Sell Stocks for November 22nd

ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024.

3 months ago · seekingalpha.com

Q3 2024 Earnings: Hold Akebia Therapeutics

Akebia Therapeutics, Inc.'s stock has surged nearly 35% after positive updates on its Vafseo (vadadustat) and promising third-quarter results, despite macroeconomic challenges. The company is expandin...